The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies.
 
Vincent T Ma
Honoraria - Conquer Cancer, the ASCO Foundation; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Bristol Myers Squibb; General Dynamics Information Technology; Immunocore; Incyte; Partner Therapeutics; Regeneron; Replimune; Targeted Oncology; Teiko.bio
Research Funding - AIQ Solutions (Inst); C4 Therapeutics (Inst); Fujifilm (Inst); Immunocore (Inst); Innate Pharma (Inst); Jounce Therapeutics (Inst); Natera (Inst); Seagen (Inst); Top Alliance BioScience (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Incyte
 
Mohammed M. Milhem
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Manuel Hidalgo
Leadership - BMS
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp.
Honoraria - Champions Oncology; InxMed; MiNK Therapeutics; Oncomatrix
Consulting or Advisory Role - Fibrogen; InxMed; KAHR Medical; MiNK Therapeutics; Oncomatrix
Research Funding - Ranok Therapeutics; TopAl
Patents, Royalties, Other Intellectual Property - Royalties from Khar Medical for IP in cell therapy; Royalties from Myriad for PALB2 patent
Travel, Accommodations, Expenses - Agenus
 
Anthony F. Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Jennifer Margaret Segar
No Relationships to Disclose
 
Maya Khalil
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Company (Inst); Cantargia AB (Inst); Caris Life Sciences (Inst); DynamiCure Biotechnology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Henlius (Inst); Henlius (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Lilly (Inst); Loxo/Lilly (Inst); Lucence (Inst); Merck (Inst); National Cancer Institute (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); Numab (Inst); Orum Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst); Xencor (Inst); Xencor (Inst)
 
Andrew A. Davis
Consulting or Advisory Role - bioTheranostics; Pfizer
 
Claire F. Verschraegen
Consulting or Advisory Role - CTI
 
Deborah J.L. Wong
Consulting or Advisory Role - Merck; Regeneron
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); Flamingo Pharma (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Kura Oncology (Inst); Lilly; Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); TopAlliance BioSciences Inc (Inst)
 
Russell J. Schilder
Consulting or Advisory Role - Celsion; Eisai; Incyte
 
Xin Gao
Consulting or Advisory Role - Arvinas; Bayer; Flare Therapeutics; Loxo/Lilly; PATHAI; PureTech; Silverback Therapeutics
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Yixing Jiang
No Relationships to Disclose
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Farrukh Tauseef Awan
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Warren Allen Chow
Other Relationship - Advenchen Laboratories; InhibRx
 
Sheng Yao
Employment - Shanghai Junshi BioSciences; TopAlliance BioSciences Inc
Leadership - Shanghai Junshi BioSciences
Stock and Other Ownership Interests - Shanghai Junshi BioSciences
 
Patricia Keegan
Employment - TopAlliance BioSciences Inc
 
Aung Naing
Employment - MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Therapeutics (I); Immune-Onc Therapeutics; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoNano Inc; OncoSec; Pharming NV (I); PsiOxus Therapeutics; PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals